Cargando…

Empagliflozin-Associated Pancreatitis: A Consideration for SGLT2 Inhibitors

Empagliflozin belongs to a class of sodium-glucose cotransporter-2 inhibitors, a medication approved by the US Food and Drug Administration in 2014 for the treatment of type 2 diabetes mellitus. Well-known side effects of this medication include symptomatic hypotension, hypoglycemia, and urinary tra...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dziadkowiec, Karolina N., Stawinski, Peter M., Proenza, Jose
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7813547/ https://www.ncbi.nlm.nih.gov/pubmed/33490300 http://dx.doi.org/10.14309/crj.0000000000000530

Ejemplares similares

Adenocarcinoma Arising From a Cervical Esophageal Inlet Patch: The Malignant Potential of a Small Lesion
por: Dziadkowiec, Karolina N, et al.
Publicado: (2020)

Correction: Adenocarcinoma Arising From a Cervical Esophageal Inlet Patch: The Malignant Potential of a Small Lesion
por: Dziadkowiec, Karolina N, et al.
Publicado: (2022)

SGLT2 Inhibitor Empagliflozin Modulates Ion Channels in Adult Zebrafish Heart
por: Karpushev, Alexey V., et al.
Publicado: (2022)

The Effects of Empagliflozin, an SGLT2 Inhibitor, on Pancreatic β-Cell Mass and Glucose Homeostasis in Type 1 Diabetes
por: Cheng, Sam Tsz Wai, et al.
Publicado: (2016)

The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats
por: Steven, Sebastian, et al.
Publicado: (2017)

Anti-Inflammatory Properties of the SGLT2 Inhibitor Empagliflozin in Activated Primary Microglia
por: Heimke, Marvin, et al.
Publicado: (2022)

COVID-19-Induced Colitis: A Novel Relationship During Troubling Times
por: Stawinski, Peter, et al.
Publicado: (2021)

Glucose lowering by SGLT2-inhibitor empagliflozin accelerates atherosclerosis regression in hyperglycemic STZ-diabetic mice
por: Pennig, Jan, et al.
Publicado: (2019)

The SGLT2 Inhibitor Empagliflozin for the Treatment of Type 2 Diabetes Mellitus: a Bench to Bedside Review
por: McGill, Janet B.
Publicado: (2014)

Haloperidol as a treatment option in cannabinoid hyperemesis syndrome
por: Stawinski, Peter, et al.
Publicado: (2022)

Left Shoulder Pain After Routine Colonoscopy: An Unusual Presentation of Splenic Laceration
por: Dziadkowiec, Karolina N, et al.
Publicado: (2020)

Determining the role of SGLT2 inhibition with Empagliflozin in the development of diabetic retinopathy
por: Matthews, Jennifer, et al.
Publicado: (2022)

The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial
por: Voors, Adriaan A., et al.
Publicado: (2022)

Structural repurposing of SGLT2 inhibitor empagliflozin for strengthening anti-heart failure activity with lower glycosuria
por: Xu, Yixiang, et al.
Publicado: (2023)

Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury
por: Aroor, Annayya R., et al.
Publicado: (2018)

Efficacy and Safety of the Use of SGLT2 Inhibitors in Patients on Incremental Hemodialysis: Maximizing Residual Renal Function, Is There a Role for SGLT2 Inhibitors?
por: De La Flor, José C., et al.
Publicado: (2023)

The SGLT2 Inhibitor Empagliflozin Ameliorates the Inflammatory Profile in Type 2 Diabetic Patients and Promotes an Antioxidant Response in Leukocytes
por: Iannantuoni, Francesca, et al.
Publicado: (2019)

Empagliflozin: a new sodium-glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes
por: Neumiller, Joshua J
Publicado: (2014)

Postprandial Glucose and Triglyceride Increases Along with the Endothelial Malfunction were Attenuated by the Administration of SGLT2 Inhibitor, Empagliflozin
por: Masuda, Daisaku, et al.
Publicado: (2020)

The SGLT2 inhibitor empagliflozin improves cardiac energy status via mitochondrial ATP production in diabetic mice
por: Choi, Jungmi, et al.
Publicado: (2023)

Empagliflozin, calcium, and SGLT1/2 receptor affinity: another piece of the puzzle
por: Anker, Stefan D., et al.
Publicado: (2018)

Empagliflozin and Protecting Microvascular Support of Heart Mechanics: SGLT2 Inhibition or More?
por: Mantsounga, Chris Sorel, et al.
Publicado: (2019)

Gastrointestinal Stromal Tumor (GIST) Causing Obscure Gastrointestinal Bleeding: An Uncommon Way of Diagnosing An Uncommon Disease
por: Dziadkowiec, Karolina N, et al.
Publicado: (2020)

Prolonged ketosis and glycosuria secondary to SGLT2 inhibitor therapy
por: Bobrowski, David, et al.
Publicado: (2021)

Sodium/glucose Co-Transporter 2 Inhibitor, Empagliflozin, Alleviated Transient Expression of SGLT2 after Myocardial Infarction
por: Lee, Soo Yong, et al.
Publicado: (2020)

Clinical Study of Metabolic Parameters, Leptin and the SGLT2 Inhibitor Empagliflozin among Patients with Obesity and Type 2 Diabetes
por: Szekeres, Zsolt, et al.
Publicado: (2023)

Empagliflozin Increases Cardiac Energy Production in Diabetes: Novel Translational Insights Into the Heart Failure Benefits of SGLT2 Inhibitors
por: Verma, Subodh, et al.
Publicado: (2018)

Is Multiple Sclerosis an Extra-Intestinal Manifestation of Inflammatory Bowel Disease? Food for Thought
por: Dziadkowiec, Karolina N, et al.
Publicado: (2020)

Impact of the SGLT2-inhibitor empagliflozin on inflammatory biomarkers after acute myocardial infarction – a post-hoc analysis of the EMMY trial
por: Benedikt, Martin, et al.
Publicado: (2023)

Hypertriglyceridemia in equines with refractory hyperinsulinemia treated with SGLT2 inhibitors
por: Kellon, Eleanor M., et al.
Publicado: (2023)

Empagliflozin and Decreased Risk of Nephrolithiasis: A Potential New Role for SGLT2 Inhibition?
por: Balasubramanian, Priyadarshini, et al.
Publicado: (2022)

Baseline neutrophil‐to‐lymphocyte ratio and efficacy of SGLT2 inhibition with empagliflozin on cardiac remodelling
por: Verma, Raj, et al.
Publicado: (2023)

A Rare but Life-Threatening Case of Fournier’s Gangrene Caused by Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor, Empagliflozin
por: Jahir, Tahmina, et al.
Publicado: (2022)

Barrett’s Esophagus: An Updated Review
por: Stawinski, Peter M., et al.
Publicado: (2023)

Euglycemic Diabetic Ketoacidosis after Discontinuing SGLT2 Inhibitor
por: Alhemeiri, Mohamed, et al.
Publicado: (2022)

The Treatment With the SGLT2 Inhibitor Empagliflozin Modifies the Hepatic Metabolome of Male Zucker Diabetic Fatty Rats Towards a Protective Profile
por: Aragón-Herrera, Alana, et al.
Publicado: (2022)

Combined treatment with DPP-4 inhibitor linagliptin and SGLT2 inhibitor empagliflozin attenuates neointima formation after vascular injury in diabetic mice
por: Takahashi, Hiroyuki, et al.
Publicado: (2019)

SGLT2 Inhibitor Empagliflozin and DPP4 Inhibitor Linagliptin Reactivate Glomerular Autophagy in db/db Mice, a Model of Type 2 Diabetes
por: Korbut, Anton I., et al.
Publicado: (2020)

SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart
por: Li, Chenguang, et al.
Publicado: (2019)

Correction to: Empagliflozin and Decreased Risk of Nephrolithiasis: A Potential New Role for SGLT2 Inhibition?
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_d2rin8seb8qiro98jj8tguoadm